FORM PTO-1449 (Modified) US Patent and Trademark Office	US DEPARTMENT OF COMMERCE	Docket No. 50623.379	Application No. 09/918,365
INFORMATION DISCLOSURE CITATION in an Application (Use several sheets if necessary)		Applicant Michal et al.	
		Filing Date July 30, 2001	Group Art Unit 1762

U.S. PATENT DOCUMENTS

Examiner Initial	Ref No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date If Appropriate
	A1	2,072,303	3/2/37	Herrmann et al.			
	A2	2,386,454	10/9/45	Frosch et al.			
	A3	3,773,737	11/20/73	Goodman et al.			
	A4	3,849,514	11/19/74	Gray, Jr. et al.			
	A5	4,226,243	10/7/80	Shalaby et al.			
	A6	4,329,383	5/11/82	Joh			
	A7	4,343,931	8/10/82	Barrows			
	A8	4,529,792	7/16/85	Barrows			
	A9	4,611,051	9/9/86	Hayes et al.			
	A10	4,656,242	4/7/87	Swan et al.			
	A11	4,733,665	3/29/88	Palmaz			
	A12	4,800,882	1/31/89	Gianturco			
	A13	4,882,168	11/21/89	Casey et al.			
	A14	4,886,062	12/12/89	Wiktor			
	A15	4,931,287	6/5/90	Bae et al.			
	A16	4,941,870	7/17/90	Okada et al.			
	A17	4,977,901	12/18/90	Ofstead			
	A18	5,019,096	5/28/91	Fox, Jr. et al.			
	A19	5,100,992	3/31/92	Cohn et al.			
	A20	5,112,457	5/12/92	Marchant			
	A21	5,133,742	7/28/92	Pinchuk			
	A22	5,163,952	11/17/92	Froix			
	A23	5,165,919	11/24/92	Sasaki et al.			
	A24	5,219,980	6/15/93	Swidler			
	A25	5,258,020	11/2/93	Froix			

	A26	5,272,012	12/21/93	Opolski			
	A27	5,292,516	3/8/94	Viegas et al.			
	A28	5,298,260	3/29/94	Viegas et al.			
	A29	5,300,295	4/5/94	Viegas et al.			
	A30	5,306,501	4/26/94	Viegas et al.			
	A31	5,306,786	4/26/94	Moens et al.			
	A32	5,328,471	7/12/94	Slepian			
	A33	5,330,768	7/19/94	Park et al.			
	A34	5,380,299	1/10/95	Fearnot et al.			
	A35	5,417,981	5/23/95	Endo et al.			
	A36	5,447,724	9/5/95	Helmus et al.			
	A37	5,455,040	10/3/95	Marchant			
	A38	5,462,990	10/31/95	Hubbell et al.			
	A39	5,464,650	11/7/95	Berg et al.			
	A40	5,485,496	1/16/96	Lee et al.			
	A41	5,516,881	5/14/96	Lee et al.			
	A42	5,569,463	10/29/96	Helmus et al.			
	A43	5,578,073	11/26/96	Haimovich et al.			
	A44	5,584,877	12/17/96	Miyake et al.			
	A45	5,605,696	2/25/97	Eury et al.			
	A46	5,607,467	3/4/97	Froix			
	A47	5,609,629	3/11/97	Fearnot et al.			
	A48	5,610,241	3/11/97	Lee et al.			
	A49	5,616,338	4/1/97	Fox, Jr. et al.			
	A50	5,624,411	4/29/97	Tuch			
	A51	5,628,730	5/13/97	Shapland et al.			
	A52	5,644,020	7/1/97	Timmermann et al.			
	A53	5,649,977	7/22/97	Campbell			
	A54	5,658,995	8/19/97	Kohn et al.			
	A55	5,667,767	9/16/97	Greff et al.			
	A56	5,670,558	9/23/97	Onishi et al.			
	A57	5,674,242	10/7/97	Phan et al.			

	A58	5,679,400	10/21/97	Tuch			
	A59	5,700,286	12/23/97	Tartaglia et al.			
	A60	5,702,754	12/30/97	Zhong			
	A61	5,711,958	1/27/98	Cohn et al.			
	A62	5,716,981	2/10/98	Hunter et al.			
	A63	5,721,131	2/24/98	Rudolph et al.			
	A64	5,723,219	3/3/98	Kolluri et al.			
	A65	5,735,897	4/7/98	Buirge			
	A66	5,746,998	5/5/98	Torchilin et al.			
	A67	5,759,205	6/2/98	Valentini			
	A68	5,776,184	7/7/98	Tuch			
	A69	5,783,657	7/21/98	Pavlin et al.			
	A70	5,788,979	8/4/98	Alt et al.			
	A71	5,800,392	9/1/98	Racchini			
	A72	5,820,917	10/13/98	Tuch			
	A73	5,824,048	10/20/98	Tuch			
	A74	5,824,049	10/20/98	Ragheb et al.			
	A75	5,830,178	11/3/98	Jones et al.			
	A76	5,837,008	11/17/98	Berg et al.			
	A77	5,837,313	11/17/98	Ding et al.			
	A78	5,849,859	12/15/98	Acemoglu			
	A79	5,851,508	12/22/98	Greff et al.			
	A80	5,854,376	12/29/98	Higashi			
	A81	5,857,998	1/12/99	Barry			
	A82	5,858,746	1/12/99	Hubbell et al.			
	A83	5,865,814	2/2/99	Tuch			
	A84	5,869,127	2/9/99	Zhong			
	A85	5,873,904	2/23/99	Ragheb et al.			
	A86	5,876,433	3/2/99	Lunn			
	A87	5,877,224	3/2/99	Brocchini et al.			
	A88	5,879,713	3/9/99	Roth et al.			
	A89	5,902,875	5/11/99	Roby et al.			

	A90	5,905,168	5/18/99	Dos Santos et al.			
	A91	5,910,564	6/8/99	Gruning et al.			
	A92	5,914,387	6/22/99	Roby et al.			
	A93	5,919,893	7/6/99	Roby et al.			
	A94	5,925,720	7/20/99	Kataoka et al.			
	A95	5,932,299	8/3/99	Katoot			
	A96	5,955,509	9/21/99	Webber et al.			
	A97	5,958,385	9/28/99	Tondeur et al.			
	A98	5,962,138	10/5/99	Kolluri et al.			
	A99	5,971,954	10/26/99	Conway et al.			
	A100	5,980,928	11/9/99	Terry			
	A101	5,980,972	11/9/99	Ding			
	A102	5,997,517	12/7/99	Whitbourne			
	A103	6,010,530	1/4/00	Goicoechea			
	A104	6,011,125	1/4/00	Lohmeijer et al.			
	A105	6,015,541	1/18/00	Greff et al.			
	A106	6,033,582	3/7/00	Lee et al.			
	A107	6,034,204	3/7/00	Mohr et al.			
	A108	6,042,875	3/28/00	Ding et al.			
	A109	6,051,576	4/18/00	Ashton et al.			
	A110	6,051,648	4/18/00	Rhee et al.			
	A111	6,054,553	4/25/00	Groth et al.			
	A112	6,056,993	5/2/00	Leidner et al.			
	A113	6,060,451	5/9/00	DiMaio et al.			
	A114	6,060,518	5/9/00	Kabanov et al.			
	A115	6,080,488	6/27/00	Hostettler et al.			
	A116	6,096,070	8/1/00	Ragheb et al.			
	A117	6,099,562	8/8/00	Ding et al.			
	A118	6,110,188	8/29/00	Narciso, Jr.			
	A119	6,110,483	8/29/00	Whitbourne et al.			
	A120	6,113,629	9/5/00	Ken			
	A121	6,120,491	9/19/00	Kohn et al.			

	A122	6,120,536	9/19/00	Ding et al.			
	A123	6,120,788	9/19/00	Barrows			
	A124	6,120,904	9/19/00	Hostettler et al.			
	A125	6,121,027	9/19/00	Clapper et al.			
	A126	6,129,761	10/10/00	Hubbell			
	A127	6,136,333	10/24/00	Cohn et al.			
	A128	6,143,354	11/7/00	Koulik et al.			
	A129	6,153,252	11/28/00	Hossainy et al.			
	A130	6,159,978	12/12/00	Myers et al.			
	A131	6,165,212	12/26/00	Dereume et al.			
	A132	6,172,167	1/9/01	Stapert et al.			
	A133	6,177,523	1/23/01	Reich et al.			
	A134	6,180,632	1/30/01	Myers et al.			
	A135	6,203,551	3/20/01	Wu			
	A136	6,211,249	4/3/01	Cohn et al.			
	A137	6,214,901	4/10/01	Chudzik et al.			
	A138	6,231,600	5/15/01	Zhong			
	A139	6,240,616	6/5/01	Yan			
	A140	6,245,753	6/12/01	Byun et al.			
	A141	6,245,760	6/12/01	He et al.			
	A142	6,248,129	6/19/01	Froix			
	A143	6,251,136	6/26/01	Guruwaiya et al.			
	A144	6,254,632	7/3/01	Wu et al.			
	A145	6,258,121	7/10/01	Yang et al.			
	A146	6,258,371	7/10/01	Koulik et al.			
	A147	6,262,034	7/17/01	Mathiowitz et al.			
	A148	6,270,788	8/7/01	Koulik et al.			
	A149	6,277,449	8/21/01	Kolluri et al.			
	A150	6,283,947	9/4/01	Mirzaee			
	A151	6,283,949	9/4/01	Roorda			
	A152	6,284,305	9/4/01	Ding et al.			

	A153	6,287,628	9/11/01	Hossainy et al.			
	A154	6,299,604	10/9/01	Ragheb et al.			
	A155	6,306,176	10/23/01	Whitbourne			
	A156	6,331,313	12/18/01	Wong et al.			
	A157	6,335,029	1/1/02	Kamath et al.			
	A158	6,344,035	2/5/02	Chudzik et al.			
	A159	6,346,110	2/12/02	Wu			
	A160	6,358,556	3/19/02	Ding et al.			
	A161	6,379,381	4/30/02	Hossainy et al.			
	A162	6,387,379	5/14/02	Goldberg et al.			
	A163	6,395,326	5/28/02	Castro et al.			
	A164	6,419,692	7/16/02	Yang et al.			
	A165	6,451,373	9/17/02	Hossainy et al.			
	A166	6,482,834	11/19/02	Spada et al.			
	A167	6,494,862	12/17/02	Ray et al.			
	A168	6,503,538	1/7/03	Chu et al.			
	A169	6,503,556	1/7/03	Harish et al.			
	A170	6,503,954	1/7/03	Bhat et al.			
	A171	6,506,437	1/14/03	Harish et al.			
	A172	6,524,347	2/25/03	Myers et al.			
	A173	6,527,801	3/4/03	Dutta			
	A174	6,527,863	3/4/03	Pacetti et al.			
	A175	6,528,526	3/4/03	Myers et al.			
	A176	6,530,950	3/11/03	Alvarado et al.			
	A177	6,530,951	3/11/03	Bates et al.			
	A178	6,540,776	4/1/03	Sanders Millare et al.			
	A179	6,544,223	4/8/03	Kokish			
	A180	6,544,543	4/8/03	Mandrusov et al.			
	A181	6,544,582	4/8/03	Yoe			
	A182	6,555,157	4/29/03	Hossainy			
	A183	6,558,733	5/6/03	Hossainy et al.			

	A184	6,565,659	5/20/03	Pacetti et al.			6/28/01
	A185	6,572,644	6/3/03	Moein			6/27/01
	A186	6,585,755	7/1/03	Jackson et al.			6/29/01
	A187	6,585,765	7/1/03	Hossainy et al.			6/29/00
	A188	6,585,926	7/1/03	Mirzaee			8/31/00
	A189	6,605,154	8/12/03	Villareal			5/31/01
	A190	6,623,448	9/23/03	Slater			3/30/01
	A191	6,625,486	9/23/03	Lundkvist et al.			4/11/01
	A192	6,645,135	11/11/03	Bhat			3/30/01
	A193	6,645,195	11/11/03	Bhat et al.			1/5/01
	A194	6,656,216	12/2/03	Hossainy et al.			6/29/01
	A195	6,656,506	12/2/03	Wu et al.			5/09/01
	A196	6,660,034	12/9/03	Mandrusov et al.			4/30/01
	A197	6,663,662	12/16/03	Pacetti et al.			12/28/00
	A198	6,666,880	12/23/03	Chiu et al.			6/19/01
	A199	6,673,154	1/6/04	Pacetti et al.			6/28/01
	A200	6,673,385	1/6/04	Ding et al.			6/28/01
	A201	6,689,099	2/10/04	Mirzaee			2/27/01
	A202	6,695,920	2/24/04	Pacetti et al.			6/27/01
	A203	6,706,013	3/16/04	Bhat et al.			6/29/01
	A204	6,712,845	3/30/04	Hossainy			4/24/01
	A205	6,713,119	3/30/04	Hossainy et al.			12/23/99
	A206	6,716,444	4/6/04	Castro et al.			9/28/00
	A207	6,740,040	5/25/04	Mandrusov et al.			1/30/01
	A208	6,743,462	6/1/04	Pacetti			5/31/01
	A209	6,749,626	6/15/04	Bhat et al.			11/17/00
	A210	6,758,859	7/6/04	Dang et al.			10/30/00
	A211	6,759,054	7/6/04	Chen et al.			12/28/00

	A212	6,764,505	7/20/04	Hossainy et al.			4/12/01
	A213	6,887,485	5/3/05	Fitzhugh et al.			5/25/01
	A214	6,899,731	5/31/05	Li et al.			1/2/01

U.S. PATENT APPLICATION PUBLICATION DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Publication	Name	Class	Subclass	Filing Date If Appropriate
	A215	2001/0051608	12/13/01	Mathiowitz et al.			10/15/98
	A216	2002/0077693	6/20/02	Barclay et al.			12/19/00
	A217	2001/0007083	7/5/01	Roorda			12/21/00
	A218	2002/0009604	1/24/02	Zamora et al.			12/21/00
	A219	2002/0120326	8/29/02	Michal			12/22/00
	A220	2001/0014717	8/16/01	Hossainy et al.			12/28/00
	A221	2001/0018469	8/30/01	Chen et al.			12/28/00
	A222	2002/0123801	9/5/02	Pacetti et al.			12/28/00
	A223	2002/0087123	7/4/02	Hossainy et al.			1/2/01
	A224	2003/0032767	2/13/03	Tada et al.			2/5/01
	A225	2001/0020011	9/6/01	Mathiowitz et al.			3/23/01
	A226	2002/0142039	10/3/02	Claude			3/30/01
	A227	2002/0155212	10/24/02	Hossainy			4/24/01
	A228	2001/0029351	10/11/01	Falotico et al.			5/7/01
	A229	2002/0005206	1/17/02	Falotico et al.			5/7/01
	A230	2002/0007213	1/17/02	Falotico et al.			5/7/01
	A231	2002/0007214	1/17/02	Falotico			5/7/01
	A232	2002/0007215	1/17/02	Falotico et al.			5/7/01
	A233	2002/0016625	2/7/02	Falotico et al.			5/7/01
	A234	2002/0032414	3/14/02	Ragheb et al.			5/7/01
	A235	2002/0188277	12/12/02	Roorda et al.			5/18/01
	A236	2002/0183581	12/5/02	Yoe et al.			5/31/01
	A237	2001/0037145	11/1/01	Guruwaiya et al.			6/21/01
	A238	2002/0165608	11/7/02	Llanos et al.			6/22/01
	A239	2002/0071822	6/13/02	Uhrich			7/27/01

FOREIGN PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation	
							Yes	No

	B1	2001-190687	7/17/01	Japan (English Abstract)				
	B2	DE 42 24 401	1/27/94	Germany				
	B3	EP 0 301 856	2/1/89	EPO				
	B4	EP 0 396 429	11/7/90	EPO				
	B5	EP 0 514 406	11/25/92	EPO				
	B6	EP 0 604 022	6/29/94	EPO				
	B7	EP 0 623 354	11/9/94	EPO				
	B8	EP 0 665 023	8/2/95	EPO				
	B9	EP 0 701 802	3/20/96	EPO				
	B10	EP 0 716 836	6/19/96	EPO				
	B11	EP 0 809 999	12/3/97	EPO				
	B12	EP 0 832 655	4/1/98	EPO				
	B13	EP 0 850 651	7/1/98	EPO				
	B14	EP 0 879 595	11/25/98	EPO				
	B15	EP 0 910 584	4/28/99	EPO				
	B16	EP 0 923 953	6/23/99	EPO				
	B17	EP 0 953 320	11/3/99	EPO				
	B18	EP 0 970 711	1/12/00	EPO				
	B19	EP 0 982 041	3/1/00	EPO				
	B20	EP 1 023 879	8/2/00	EPO				
	B21	EP 1 192 957	4/3/02	EPO				
	B22	EP 1 273 314	1/8/03	EPO				
	B23	SU 790725	2/9/83	SU (English Abstract)				
	B24	SU 811750	9/23/83	SU (English Abstract)				
	B25	SU 872531	10/15/81	SU (English Abstract)				
	B26	SU 876663	10/30/81	SU (English Abstract)				
	B27	SU 905228	2/15/82	SU (English Abstract)				
	B28	SU 1016314	5/7/83	SU (English Abstract)				
	B29	SU 1293518	2/28/87	SU (English Abstract)				
	B30	WO 91/12846	9/5/91	PCT				
	B31	WO 94/09760	5/11/94	PCT				
	B32	WO 95/10989	4/27/95	PCT				

	B33	WO 95/24929	9/21/95	PCT				
	B34	WO 96/40174	12/19/96	PCT				
	B35	WO 97/10011	3/20/97	PCT				
	B36	WO 97/45105	12/4/97	PCT				
	B37	WO 97/46590	12/11/97	PCT				
	B38	WO 98/08463	3/5/98	PCT				
	B39	WO 98/17331	4/30/98	PCT				
	B40	WO 98/32398	7/30/98	PCT				
	B41	WO 98/36784	8/27/98	PCT				
	B42	WO 99/01118	1/14/99	PCT				
	B43	WO 99/38546	8/5/99	PCT				
	B44	WO 99/63981	12/16/99	PCT				
	B45	WO 00/02599	1/20/00	PCT				
	B46	WO 00/12147	3/9/00	PCT				
	B47	WO 00/18446	4/6/00	PCT				
	B48	WO 00/64506	11/2/00	PCT				
	B49	WO 01/01890	1/11/01	PCT				
	B50	WO 01/15751	3/8/01	PCT				
	B51	WO 01/17577	3/15/01	PCT				
	B52	WO 01/45763	6/28/01	PCT				
	B53	WO 01/49338	7/12/01	PCT				
	B54	WO 01/51027	7/19/01	PCT				
	B55	WO 01/74414	10/11/01	PCT				
	B56	WO 02/003890	1/17/02	PCT				
	B57	WO 02/026162	4/4/02	PCT				
	B58	WO 02/034311	5/2/02	PCT				
	B59	WO 02/056790	7/25/02	PCT				
	B60	WO 02/058753	8/1/02	PCT				
	B61	WO 02/102283	12/27/02	PCT				
	B62	WO 03/000308	1/3/03	PCT				
	B63	WO 03/022323	3/20/03	PCT				
	B64	WO 03/028780	4/10/03	PCT				

	B65	WO 03/037223	5/8/03	PCT				
	B66	WO 03/039612	5/15/03	PCT				
	B67	WO 03/080147	10/2/03	PCT				
	B68	WO 03/082368	10/9/03	PCT				
	B69	WO 04/000383	12/31/03	PCT				
	B70	WO 04/009145	1/29/04	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	C1	Anonymous, *Cardiologists Draw - Up The Dream Stent*, Clinica 710:15 (June 17, 1996), http://www.dialogweb.com/cgi/document?req=1061848202959, printed 8/25/03 (2 pages).
	C2	Anonymous, *Heparin-coated stents cut complications by 30%*, Clinica 732:17 (Nov. 18, 1996), http://www.dialogweb.com/cgi/document?req=1061847871753, printed 8/25/03 (2 pages).
	C3	Anonymous, *Rolling Therapeutic Agent Loading Device for Therapeutic Agent Delivery or Coated Stent* (Abstract 434009), Res. Disclos. pp. 974-975 (June 2000).
	C4	Anonymous, *Stenting continues to dominate cardiology*, Clinica 720:22 (Sept. 2, 1996), http://www.dialogweb.com/cgi/document?req=1061848017752, printed 8/25/03 (2 pages).
	C5	Aoyagi et al., *Preparation of cross-linked aliphatic polyester and application to thermo-responsive material*, Journal of Controlled Release 32:87-96 (1994).
	C6	Barath et al., *Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury*, JACC 13(2): 252A (Abstract) (Feb. 1989).
	C7	Barbucci et al., *Coating of commercially available materials with a new heparinizable material*, J. Biomed. Mater. Res. 25:1259-1274 (Oct. 1991).
	C8	Chung et al., *Inner core segment design for drug delivery control of thermo-responsive polymeric micelles*, Journal of Controlled Release 65:93-103 (2000).
	C9	Dev et al., *Kinetics of Drug Delivery to the Arterial Wall Via Polyurethane-Coated Removable Nitinol Stent: Comparative Study of Two Drugs*, Catheterization and Cardiovascular Diagnosis 34:272-278 (1995).
	C10	Dichek et al., *Seeding of Intravascular Stents with Genetically Engineered Endothelial Cells*, Circ. 80(5):1347-1353 (Nov. 1989).
	C11	Eigler et al., *Local Arterial Wall Drug Delivery from a Polymer Coated Removable Metallic Stent: Kinetics, Distribution, and Bioactivity of Forskolin*, JACC, 4A (701-1), Abstract (Feb. 1994).
	C12	Helmus, *Overview of Biomedical Materials*, MRS Bulletin, pp. 33-38 (Sept. 1991).
	C13	Herdeg et al., *Antiproliferative Stent Coatings: Taxol and Related Compounds*, Semin. Intervent. Cardiol. 3:197-199 (1998).
	C14	Huang et al., *Biodegradable Polymers Derived from Aminoacids*, Macromol. Symp. 144, 7-32 (1999).
	C15	Inoue et al., *An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs*, Journal of Controlled Release 51:221-229 (1998).
	C16	Kataoka et al., *Block copolymer micelles as vehicles for drug delivery*, Journal of Controlled Release 24:119-132 (1993).
	C17	Katsarava et al., *Amino Acid-Based Bioanalogous Polymers. Synthesis and Study of Regular Poly(ester amide)s Based on Bis(α-amino acid)α,ω-Alkylene Diesters, and Aliphatic Dicarbolic Acids*, Journal of Polymer Science, Part A: Polymer Chemistry, 37(4), 391-407 (1999).
	C18	Levy et al., *Strategies For Treating Arterial Restenosis Using Polymeric Controlled Release Implants*, Biotechnol. Bioact. Polym. [Proc. Am. Chem. Soc. Symp.], pp. 259-268 (1994).

	C19	Liu et al., *Drug release characteristics of unimolecular polymeric micelles*, Journal of Controlled Release 68:167-174 (2000).
	C20	Marconi et al., *Covalent bonding of heparin to a vinyl copolymer for biomedical applications*, Biomaterials 18(12):885-890 (1997).
	C21	Matsumaru et al., *Embolic Materials For Endovascular Treatment of Cerebral Lesions*, J. Biomater. Sci. Polymer Edn 8(7):555-569 (1997).
	C22	Miyazaki et al., *Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice*, Chem. Pharm. Bull. 33(6) 2490-2498 (1985).
	C23	Miyazawa et al., *Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat*, J. Cardiovasc. Pharmacol., pp. 157-162 (1997).
	C24	Nordrehaug et al., *A novel biocompatible coating applied to coronary stents*, EPO Heart Journal 14, p. 321 (P1694), Abstr. Suppl. (1993).
	C25	Ohsawa et al., *Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty*, American Heart Journal 136(6):1081-1087 (Dec. 1998).
	C26	Ozaki et al., *New Stent Technologies*, Progress in Cardiovascular Diseases, Vol. XXXIX(2):129-140 (Sept./Oct. 1996).
	C27	Pechar et al., *Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin*, Bioconjucate Chemistry 11(2):131-139 (Mar./Apr. 2000).
	C28	Peng et al., *Role of polymers in improving the results of stenting in coronary arteries*, Biomaterials 17:685-694 (1996).
	C29	Saotome, et al., *Novel Enzymatically Degradable Polymers Comprising α-Amino Acid, 1,2-Ethanediol, and Adipic Acid*, Chemistry Letters, pp. 21-24, (1991).
	C30	Shigeno, *Prevention of Cerebrovascular Spasm By Bosentan, Novel Endothelin Receptor*, Chemical Abstract 125:212307 (1996).
	C31	van Beusekom et al., *Coronary stent coatings*, Coronary Artery Disease 5(7):590-596 (July 1994).
	C32	Wilensky et al., *Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries*, Trends Cardiovasc. Med. 3(5):163-170 (1993).
	C33	Yokoyama et al., *Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor*, Journal of Controlled Release 50:79-92 (1998).

EXAMINER	DATE CONSIDERED
ERMA CAMERON	8/15/2007

EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.